BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15162151)

  • 1. A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
    Liggins AP; Brown PJ; Asker K; Pulford K; Banham AH
    Br J Cancer; 2004 Jul; 91(1):141-9. PubMed ID: 15162151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
    Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Lawrie C; Moir D; Hatton C; Banham AH; Pulford K
    Br J Haematol; 2009 Aug; 146(4):396-407. PubMed ID: 19552722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
    Liggins AP; Cooper CD; Lawrie CH; Brown PJ; Collins GP; Hatton CS; Pulford K; Banham AH
    Br J Haematol; 2007 Aug; 138(4):479-86. PubMed ID: 17608765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
    Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Cabes M; Lawrie CH; Moir D; Hatton C; Banham AH; Pulford K
    Haematologica; 2011 Jan; 96(1):78-86. PubMed ID: 20851862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
    Joseph-Pietras D; Gao Y; Zojer N; Ait-Tahar K; Banham AH; Pulford K; Rice J; Savelyeva N; Sahota SS
    Leukemia; 2010 Nov; 24(11):1951-9. PubMed ID: 20861911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics.
    Booman M; Douwes J; Glas AM; de Jong D; Schuuring E; Kluin PM
    J Pathol; 2006 Oct; 210(2):163-71. PubMed ID: 16823896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
    Watanuki-Miyauchi R; Kojima Y; Tsurumi H; Hara T; Goto N; Kasahara S; Saio M; Moriwaki H; Takami T
    Pathol Int; 2005 Jun; 55(6):324-30. PubMed ID: 15943789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
    Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A
    Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomic analysis of human sarcoma.
    Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.
    Guinn BA; Bland EA; Lodi U; Liggins AP; Tobal K; Petters S; Wells JW; Banham AH; Mufti GJ
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1293-304. PubMed ID: 16112646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
    Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
    Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a novel cancer/testis antigen gene CAGE.
    Cho B; Lim Y; Lee DY; Park SY; Lee H; Kim WH; Yang H; Bang YJ; Jeoung DI
    Biochem Biophys Res Commun; 2002 Apr; 292(3):715-26. PubMed ID: 11922625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic detection of diffuse large B-cell lymphoma-associated antigens.
    Liggins AP; Guinn BA; Hatton CS; Pulford K; Banham AH
    Int J Cancer; 2004 Jul; 110(4):563-9. PubMed ID: 15122589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
    Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
    Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.
    Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.